Nigel Sharfe1, Ariana Karanxha1, Harjit Dadi1, Daniele Merico2, David Chitayat3, Jo-Anne Herbrick4, Spencer Freeman5, Sergio Grinstein5, Chaim M Roifman6. 1. Canadian Centre for Primary Immunodeficiency, Immunogenomic Laboratory, Division of Immunology & Allergy, Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada. 2. Centre for Applied Genomics, Hospital for Sick Children, Toronto, Ontario, Canada; Deep Genomics, Inc, Toronto, Ontario, Canada. 3. Clinical and Metabolic Genetics, Hospital for Sick Children, Toronto, Ontario, Canada. 4. Centre for Applied Genomics, Hospital for Sick Children, Toronto, Ontario, Canada. 5. The Program in Cell Biology, Hospital for Sick Children, Toronto, Ontario, Canada. 6. Canadian Centre for Primary Immunodeficiency, Immunogenomic Laboratory, Division of Immunology & Allergy, Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada. Electronic address: chaim.roifman@sickkids.ca.
Abstract
BACKGROUND: We previously reported a novel syndrome characterized by combined immunodeficiency associated with severe developmental defects-subsequently known as Roifman-Chitayat syndrome (RCS; OMIM 613328). Linkage analysis identified 2 disease-associated loci. OBJECTIVES: We sought to identify the genetic defect in these patients and characterize their immunologic cellular abnormalities. METHODS: Genetic, immunologic, protein, and cellular functional analyses were used to identify and characterize patient genetic deficiencies and aberrant patient cell behavior. RESULTS: Deleterious variants were found at both loci identified by linkage analysis: a homozygous stop codon in PI3-kinase p110δ (PIK3CD) and a homozygous frame shift mutation in SKAP (KNSTRN), both ablating protein expression. Patients with RCS display aberrant B-cell development, similar to p110δ-deficient mice, but also aberrant T-cell spreading, cell-cell interaction, and migration. Patients also display significant developmental abnormalities not seen in p110δ knockouts (eg, optic nerve atrophy and skeletal anomalies) that we ascribe to loss of SKAP. Aberrant SKAP expression can prolong anaphase and this may contribute to developmental defects. However, we also identified microtubule-associated protein 4 microtubule-binding protein as a novel SKAP-binding partner and show that it undergoes relocalization in patient T cells, with associated areas of aberrant microtubule hyperstabilization, likely contributing not only to the altered properties of RCS lymphoid cells but also to developmental defects. CONCLUSIONS: The complex RCS presentation, with combined developmental and immunologic defects, is associated with a combined deficiency of 2 genes products, PI3-kinase p110δ and SKAP, both of which appear to play a significant role in the disease.
BACKGROUND: We previously reported a novel syndrome characterized by combined immunodeficiency associated with severe developmental defects-subsequently known as Roifman-Chitayat syndrome (RCS; OMIM 613328). Linkage analysis identified 2 disease-associated loci. OBJECTIVES: We sought to identify the genetic defect in these patients and characterize their immunologic cellular abnormalities. METHODS: Genetic, immunologic, protein, and cellular functional analyses were used to identify and characterize patientgenetic deficiencies and aberrant patient cell behavior. RESULTS: Deleterious variants were found at both loci identified by linkage analysis: a homozygous stop codon in PI3-kinase p110δ (PIK3CD) and a homozygous frame shift mutation in SKAP (KNSTRN), both ablating protein expression. Patients with RCS display aberrant B-cell development, similar to p110δ-deficient mice, but also aberrant T-cell spreading, cell-cell interaction, and migration. Patients also display significant developmental abnormalities not seen in p110δ knockouts (eg, optic nerve atrophy and skeletal anomalies) that we ascribe to loss of SKAP. Aberrant SKAP expression can prolong anaphase and this may contribute to developmental defects. However, we also identified microtubule-associated protein 4 microtubule-binding protein as a novel SKAP-binding partner and show that it undergoes relocalization in patient T cells, with associated areas of aberrant microtubule hyperstabilization, likely contributing not only to the altered properties of RCS lymphoid cells but also to developmental defects. CONCLUSIONS: The complex RCS presentation, with combined developmental and immunologic defects, is associated with a combined deficiency of 2 genes products, PI3-kinase p110δ and SKAP, both of which appear to play a significant role in the disease.
Authors: Stuart G Tangye; Julia Bier; Anthony Lau; Tina Nguyen; Gulbu Uzel; Elissa K Deenick Journal: J Clin Immunol Date: 2019-03-25 Impact factor: 8.317
Authors: David J Swan; Dominik Aschenbrenner; Christopher A Lamb; Krishnendu Chakraborty; Jonathan Clark; Sumeet Pandey; Karin R Engelhardt; Rui Chen; Athena Cavounidis; Yuchun Ding; Natalio Krasnogor; Christopher D Carey; Meghan Acres; Stephanie Needham; Andrew J Cant; Peter D Arkwright; Anita Chandra; Klaus Okkenhaug; Holm H Uhlig; Sophie Hambleton Journal: Haematologica Date: 2019-05-09 Impact factor: 9.941
Authors: Sarah Beaussant Cohen; Wayne Bainter; Jared L Johnson; Ting-Yu Lin; Jenny C Y Wong; Jacqueline G Wallace; Jennifer Jones; Sonia Qureshi; Fatima Mir; Farah Qamar; Lewis C Cantley; Raif S Geha; Janet Chou Journal: J Allergy Clin Immunol Date: 2018-10-16 Impact factor: 10.793
Authors: Bart Vanhaesebroeck; Matthew W D Perry; Jennifer R Brown; Fabrice André; Klaus Okkenhaug Journal: Nat Rev Drug Discov Date: 2021-06-14 Impact factor: 112.288
Authors: Paul Tuijnenburg; Daan J Aan de Kerk; Machiel H Jansen; Ben Morris; Cor Lieftink; Roderick L Beijersbergen; Ester M M van Leeuwen; Taco W Kuijpers Journal: Eur J Immunol Date: 2019-11-14 Impact factor: 5.532